See more : Electrotherm (India) Limited (ELECTHERM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of BioSig Technologies, Inc. (BSGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioSig Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Alexco Resource Corp. (AXU.TO) Income Statement Analysis – Financial Results
- IsoEnergy Ltd. (ISO.V) Income Statement Analysis – Financial Results
- Shinyoungwacoal,Inc. (005800.KS) Income Statement Analysis – Financial Results
- Harmony Capital Services Limited (HRMNYCP.BO) Income Statement Analysis – Financial Results
- Octanex Limited (OXX.AX) Income Statement Analysis – Financial Results
BioSig Technologies, Inc. (BSGM)
About BioSig Technologies, Inc.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 18.00K | 286.00K | 441.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 57.00K | 199.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 0.00 | 0.00 | 0.00 | 6.80K |
Gross Profit | 18.00K | 229.00K | 242.00K | -550.00K | -54.35K | -12.40K | -11.70K | -10.48K | -10.48K | 0.00 | 0.00 | 0.00 | -6.80K |
Gross Profit Ratio | 100.00% | 80.07% | 54.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 5.09M | 5.82M | 5.60M | 18.14M | 9.74M | 4.37M | 4.76M | 2.65M | 1.24M | 548.00K | 992.21K | 888.95K | 582.53K |
General & Administrative | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.29M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.41K | 0.00 |
SG&A | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.36M | 484.13K |
Other Expenses | 361.00K | 293.00K | 198.00K | 94.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 0.00 | 0.00 |
Operating Expenses | 28.53M | 27.49M | 33.65M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
Cost & Expenses | 28.53M | 27.55M | 33.85M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
Interest Income | 9.00K | 3.00K | 2.00K | 45.00K | 132.75K | 10.90K | 75.00 | 1.00 | 1.30K | 11.03K | 70.06K | 124.17K | 171.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.90K | 75.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 361.00K | 666.00K | 639.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 10.02K | 6.80K |
EBITDA | -28.15M | -26.97M | -33.21M | -58.63M | -34.42M | -17.25M | -13.11M | -10.73M | -9.45M | -7.85M | -6.22M | -2.25M | -1.14M |
EBITDA Ratio | -156,394.44% | -9,430.77% | -7,656.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -28.51M | -27.27M | -33.41M | -59.18M | -34.60M | -17.26M | -12.91M | -11.16M | -12.04M | -7.87M | -6.24M | -2.26M | -1.07M |
Operating Income Ratio | -158,400.00% | -9,533.22% | -7,576.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -178.00K | 3.00K | 555.00K | 44.00K | 133.20K | 10.90K | 210.54K | -422.91K | 2.58M | -604.80K | -3.57M | -124.17K | -77.76K |
Income Before Tax | -28.69M | -27.26M | -32.86M | -59.14M | -34.47M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.39M | -1.15M |
Income Before Tax Ratio | -159,388.89% | -9,532.17% | -7,450.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 9.00K | -1.49M | -6.97M | -549.05K | 21.79K | -210.54K | 422.91K | -2.58M | 11.03K | 70.06K | 90.86K | 0.00 |
Net Income | -29.04M | -27.27M | -31.36M | -52.17M | -33.92M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.48M | -1.15M |
Net Income Ratio | -161,338.89% | -9,535.31% | -7,111.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
EPS Diluted | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
Weighted Avg Shares Out | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
Weighted Avg Shares Out (Dil) | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
BioSig to Host Live Roundtable Webinar to Discuss Clinical Data Delivered With Its Signal Processing Technology For Arrhythmia Care
BioSig Technologies adds to its growing clinical footprint in Texas
BioSig Adds To Its Clinical Footprint In Texas
BioSig Technologies installs its PURE EP system at renowned Boston medical center
BioSig Installs its Signal Processing Technology for Arrhythmia Care at a Leading Hospital in Boston
BioSig Expands its Installation Base in Texas
BioSig Technologies looking to unlock the future of bioelectronic medicine
BioSig Increases Case Volume Estimates
Clinical Data Published in the Journal of Cardiovascular Electrophysiology Could Be Important for This Stock
BioSig's PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias
Source: https://incomestatements.info
Category: Stock Reports